Clene(CLNN) Stock Price Today | Quotes & News

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US Stock MarketDetailed Quotes

CLNN Clene

Watchlist

3.5600
-0.3600-9.18%

Trading Mar 25 12:57 ET

30.57MMarket Cap-0.63P/E (TTM)

Intraday

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Clene to Participate in Jones Las Vegas Technology and Innovation Conference on April 8-9, 2025
Yahoo FinanceMar 25 08:30 ET
H.C. Wainwright Sticks to Their Buy Rating for Clene (CLNN)
TipRanksMar 25 06:56 ET · Ratings
Clene Inc. Reports 2024 Financial Results and Strategic Plans
TipRanksMar 24 23:58 ET
Express News | Clene Inc. Files for Mixed Shelf of up to $160 Mln - SEC Filing
ReutersMar 24 16:50 ET
10-K: FY2024 Annual Report
SECMar 24 16:04 ET · Announcements
Clene Price Target Maintained With a $31.00/Share by HC Wainwright & Co.
Dow JonesMar 24 15:08 ET · Ratings

Comments

Jaguar8

Mar 12 20:25

NEWS

$Clene (CLNN.US)$
Clene Announced New Evidence From A Cross-Regimen, Post Hoc Analysis Of Long-Term Survival In HEALEY ALS Platform Trial Participants
Benzinga· 17 mins ago1min
Clene(CLNN.US)
Clene, Inc. (NASDAQ:CLNN) and its subsidiary, Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced new evidence from a cross-r...

Jaguar8

Feb 25 21:04

NEWS

$Clene (CLNN.US)$
Clene and APST Enter Into an Agreement to Support FDA's Recommendation for Long-Term NfL Biomarker Analyses of CNM-Au8®'s Impact on NfL Reduction
Tuesday, 25th February at 8:00 am
Longitudinal ALS patient data from APST Research will enable a more robust analysis of the effect of CNM-Au8 on NfL biomarkers
APST Research data includes thousands of people living with ALS including clinical, survival, and longitudinal NfL data
Clene plans to analyze the APST ALS NfL biomarker a...

Trytosaveabit

Dec 11, 2024 03:21

New 425B ( Prospectus )

$Clene (CLNN.US)$ (((((((. Clene Inc. has entered into an equity distribution agreement to offer and sell up to $7.39 million of common stock through Canaccord Genuity. The at-the-market offering will be used to fund clinical development of CNM-Au8, Clene's lead drug candidate for neurological disorders like ALS and MS.
The company recently received FDA guidance on a potential accelerated approval pathway for CNM-Au8 in ALS. Clene plans to provide additional biomark...

Trytosaveabit

Dec 10, 2024 21:34

News

$Clene (CLNN.US)$ Reuters
1 min ago
FDA Provides Roadmap for Accelerated Approval Pathway Through Submission of Additional Cnm-AU8® Biomarker Data in ALS